MiraVista Diagnostics is an Industry Leading Mycology Reference Laboratory

MiraVista Diagnostics is a CLIA and CAP certified mycology reference laboratory (RL) with an exclusive focus on developing and processing diagnostic tests for serious fungal infections. We offer the highest standards in clinical accuracy and sensitivity for detection, monitoring and diagnostic testing for blastomyces dermatitidis, histoplasma capsulatum, cryptococcus, coccidioides, aspergillus and beta-D glucan.

Clinical Laboratory Testing for Serious Fungal Infections

The company was founded in 2002 by the renowned infectious disease scientist, Dr. Lawrence Joseph Wheat, whose groundbreaking research contributions resulted in the development of the first histoplasmosis antigen test in 1986. Today, MiraVista Diagnostics serves the medical and veterinary sectors in the U.S. and Canada processing over 100,000 tests per year for fungal infections. This includes antigen and antibody detection tests for coccidioides (valley fever fungus), aspergillus, histoplasmosis capsulatum, blastomyes dermatitidis and cryptococcus.

MiraVista Diagnostics offers same-day testing, prompt response, fast shipping and direct access to the laboratory’s team of experienced infectious disease specialists that has collectively published more than 1,000 scientific research articles. Clients include large medical research hospitals, healthcare systems and universities as well as large reference labs and veterinary clinics. Contact us to discuss a fungal infection case, set up a corporate account for high volume testing or order from among MiraVista Diagnostics’ menu of diagnostic screening tests for fungal diseases.

Company News

ALERT: Winter Weather May Cause Shipping Delays to MiraVista Diagnostics

Extreme winter weather conditions across the country could impact deliveries to MiraVista Diagnostics in Indianapolis, Indiana. Please check directly with your shipping carrier for alerts about service interruptions or delays that could impact your shipments to our lab. FedEx SERVICE…
READ MORE →

NIH Approved Institutional Biosafety Committee (IBC) First Meeting Scheduled for January 29

In compliance with the National Institutes of Health Office of Science Policy (NIH OSP), MiraVista Diagnostics LLC has formed an Institutional Biosafety Committee (IBC) to review, approve and confirm that the company’s research involving recombinant/synthetic DNA complies with NIH guidelines….
READ MORE →

Happy New Year From Everyone at MiraVista Diagnostics

Everyone at MiraVista Diagnostics wishes you a Happy New Year!  We hope you had a wonderful holiday season and you’re just as excited to kick off 2018 as we are. HAPPY NEW YEAR MiraVista Diagnostics has an incredible team of…
READ MORE →

MiraVista Diagnostics is Participating in 2017 ID Week in San Diego

MiraVista Diagnostics is participating in 2017 ID Week in San Diego on October 4-8, 2017. Representatives from the company’s clinical laboratory team will be available to discuss our latest mycology research and menu of diagnostic tests for serious fungal infections….
READ MORE →

MiraVista Diagnostics Supports Fungal Disease Awareness Week

August 14–18, 2017, is the first Fungal Disease Awareness Week. CDC and partners have organized this week to highlight the importance of recognizing serious fungal diseases early enough in the course of a patient’s illness to provide life-saving treatment. MiraVista…
READ MORE →

MiraVista is Participating in the 2017 Coccidioidomycosis Study Group Symposium

MiraVista Diagnostics is participating in the 2017 Coccidioidomycosis Study Group Symposium on August 11-13 at the Stanford University Medical School. Representatives from the company’s clinical laboratory will be available to discuss MiraVista’s menu of diagnostic tests for serious fungal infections….
READ MORE →

LEARN MORE
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo
  • vendor logo